🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cambridge
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cambridge

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca64 Merck Sharp & Dohme LLC26 Hoffmann-La Roche15 Janssen Research & Development, LLC15 AbbVie13
Site city
London2010 Manchester675 Birmingham472 Glasgow439 Cambridge416
All 426 cities
Target enrolment
to
416 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading
2025-08-06
Recruiting
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743Progressive Multiple Sclerosis
Autolus Limited
Phase 1
18
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Active, closed
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd
Observational
50
Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton
2025-07-31
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
AbbVie
Phase 3
120
Cambridge, Sheffield, Liverpool
2025-07-28
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Amgen
Phase 3
12,800
Birmingham, Blackpool, Bristol, Cambridge, Chester, Coventry, Dudley, Dundee
2025-07-25
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds
2025-07-21
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Nuvalent Inc.
Phase 3
450
Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham
2025-07-17
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
426
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Amgen
Phase 2
220
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
2025-07-16
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
Merck Sharp & Dohme LLC
Phase 1/2
360
Cambridge, London
2025-07-03
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Cambridge, Newcastle, Oxford
2025-07
Active, closed
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
NCT06794554Chronic Pulmonary Aspergillosis
Mundipharma Research Limited
Phase 2
60
Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester
2025-06-30
Active, closed
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531Primary Sjögren's Syndrome
Immunovant Sciences GmbH
Phase 2
180
Cambridge, Liverpool, London, Swindon, Truro
2025-06-30
Recruiting
Bladder EpiCheck European Haematuria Study
NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Nucleix Ltd.
Observational
800
Dunfermline, Cambridge, Edinburgh, London, Surrey Quays
2025-06-20
Recruiting
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
NCT06850623Locally Advanced Pancreatic Adenocarcinoma
EXACT Therapeutics AS
Phase 2
25
Cambridge, Hammersmith, Sutton
2025-06-19
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
Boehringer Ingelheim
Phase 3
1,755
Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland
2025-06-09
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth
2025-06-04
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
AstraZeneca
Phase 3
15,100
Birmingham, Bournemouth, Bridgend, Bristol, Calow, Cambridge, Cardiff, Chippenham
2025-06-04
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
Sanofi
Phase 2
99
Bury, Cambridge, London
2025-06-03
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
AbbVie
Phase 2
110
Cambridge, Exeter, London
2025-05-28
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
Pfizer
Phase 2
252
Cambridge, Manchester, London, Bradford, Crumpsall, Wakefield
2025-05-20
Rows per page Showing 76–100 of 416
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/cambridge

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.